

1. Specific Comments To Authors: Dear editors! The authors have done work on correcting inaccuracies/errors of previously published data. The data in the figures and their captions are interesting and described in a concise scientific style. Successful further scientific work to the authors.

Reply: Thank you for your comments!

2. Specific Comments To Authors: the manuscript files are not correct. Please, attach the paper

Reply: Thank you for your comments. It's a correction rereading our article "Propensity-matched analysis of patients with intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma and hepatocellular carcinoma undergoing a liver transplant". We have attached the reference below.

REFERENCES

1 Brandão ABM, Rodriguez S, Fleck Jr AM, Marroni CA, Wagner MB, Hörbe A, Fernandes MV, Cerski CT, Coral GP. Propensity-matched analysis of patients with intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma and hepatocellular carcinoma undergoing a liver transplant. World J Clin Oncol 2022; 13: 688-701

3. Specific Comments To Authors: Thanks for the opportunity to review the Correction "Propensity-matched analysis of patients with intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma and hepatocellular carcinoma undergoing a liver transplant". The authors have revised figures 3 and 4 in their Supplementary Material. It should be accepted for publication in its present form.

Reply: Thank you for your comments!

Round 2:

Specific Comments To Authors: The authors have not properly addressed the issues and queries we raised. A linguistic revision should be performed by a professional service since there are some grammar mistakes and oversights. Discussion section: Very interesting and timely discussion. Of note, the authors should expand the Discussion section, including a more personal perspective to reflect on. For example, they could answer the following questions – in order to facilitate the understanding of this complex topic to readers: what potential does this study hold? What are the knowledge gaps and how do researchers tackle them? How do you see this area unfolding in the next 5 years? We think it would be extremely interesting for the readers. Introduction section: the authors should expand and better discuss the evolving systemic treatment scenario and the molecular features of these tumors, and add some recently published papers regarding this topic (PMID: 32994319 ; PMID: 33645367; PMID: 32396398 ; PMID: 33592561)

Reply: Thank you for your comments!

This is not a new submission. We have requested publication of an erratum relating to Figures 3 and 4 of our previous article “Propensity-matched analysis of patients with intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma and hepatocellular carcinoma undergoing a liver transplant” (DOI: 10.5306/wjco.v13.i8.688), published on August 24, 2022. The images and legends of Figures 3 and 4 should be replaced. Please refer to the attached file for the correct ones. Once again, please accept our apology. Thank you very much for your understanding.